Damber J E, Bergh A, Assarsson B, Gåfvels M
Department of Urology and Andrology, University of Umeå, Sweden.
Urol Res. 1995;23(2):119-25. doi: 10.1007/BF00307942.
Epidermal growth factor receptor (EGF-R) was studied in Dunning prostatic cancer models using competitive binding assays and solution hybridization assay. EGF-R-binding capacity and mRNA were demonstrated in a hormone-sensitive R3327 prostatic tumor from both control and castrated animals while no such activity was found in the hormone-independent AT-1 tumors. Castration induced no quantitative changes in the EGF-R. Estrogen treatment induced a significant reduction of the binding capacity of EGF-R and its mRNA. It was concluded that EGF-R is present in the androgen-sensitive Dunning prostatic tumor models (R3327), but that the androgen-insensitive, undifferentiated AT-1 tumor lacks EGF-R expression. Endocrine treatment has no significant effect on the EGF-R in these tumor models.
利用竞争性结合试验和溶液杂交试验，在邓宁前列腺癌模型中对表皮生长因子受体（EGF-R）进行了研究。在对照动物和去势动物的激素敏感型R3327前列腺肿瘤中均证实了EGF-R结合能力和mRNA，而在激素非依赖型AT-1肿瘤中未发现此类活性。去势未引起EGF-R的定量变化。雌激素处理导致EGF-R及其mRNA的结合能力显著降低。得出的结论是，EGF-R存在于雄激素敏感的邓宁前列腺肿瘤模型（R3327）中，但雄激素不敏感的未分化AT-1肿瘤缺乏EGF-R表达。在这些肿瘤模型中，内分泌治疗对EGF-R没有显著影响。
